作者： sarah

Queensland, AU, August 1, 2025 - (JCN Newswire via SeaPRwire.com) - Queensland’s most significant International Education and Training (IET) and Research and Innovation (R&I) trade mission has taken to the global stage, with 38 of the state’s leading institutions and companies visiting Expo 2025 Osaka, Kansai, Japan, in July.Led by Minister for Finance, Trade, Employment and Training Ros Bates, the delegation was advancing Queensland’s global footprint through high-level meetings in Taiwan and Japan, culminating in a showcase at Expo 2025 Osaka.The visit follows the release of the Queensland-Japan Trade and Investment Strategy 2025-2028, which outlines practical steps to grow collaboration in education, research and commercialisation, matching Queensland’s strengths with Japan’s future needs.At the Australia Pavilion on July 17, Minister Bates hosted a major Queensland reception with Japan government representatives, alumni, and education leaders.This trade mission shows Queensland’s renewed commitment to international engagement, with a focus on building collaborative research partnerships, expanding student mobility, and promoting the Study Queensland brand to meet demand in Asia.This was Minister Bates’ second international trade mission to Japan, after visits to India, Korea, China and Hong Kong, and Singapore.International education remains Queensland’s biggest services export, worth $6.85 billion, and supporting around 30,000 jobs. In 2024, more than 157,000 international students from 160 countries studied in Queensland.“We’re reinforcing Queensland’s reputation as a reliable economic partner, and a favorable destination for international students and research and innovation,” Minister Bates said.“Queensland is open for learning, open for business, and ready to lead.” Expo 2025 Osaka, Kansai, Japan (www.expo2025.or.jp/en/) runs from April 13 - October 13, 2025.Contact:Illka GobiusPinpoint PRillka@pinpointpr.sg Copyright 2025 JCN Newswire via SeaPRwire.com.

Queensland, AU, August 1, 2025 - (JCN Newswire via SeaPRwire.com) - In a landmark step for international clean aviation collaboration, Queensland aerospace innovator Stralis Aircraft has officially signed a Memorandum of Understanding (MoU) with the Joint Research Center for Electric Architecture, Akita University and Akita Prefectural University, at Expo 2025 Osaka.MOU Signing Ceremony, Australia Pavilion, Expo 2025 Osaka. From left: Junichi Sakaki, Director of the Joint Research Center for Electrification Architecture, Akita University, Hon. Ros Bates, Minister for Finance, Trade, Employment and Training, Queensland, Australia, and Bob Criner, Co-founder and CEO of Stralis Aircraft. [July 17, 2025]The MoU signing was held at the Australia Pavilion in the presence of the Hon. Ros Bates MP, Queensland Minister for Finance, Trade, Employment and Training, as part of the Queensland Government's flagship international trade mission to Japan."Stralis is a great example of how Queensland businesses can lead the world in clean aviation technology. We’re backing them in order to scale, export and grow jobs," Minister Bates said. "It's not just an MoU — it's a runway for clean technology, innovation, and workforce development between Queensland and Japan."Under the agreement, Stralis will test its hydrogen-electric propulsion components at one of Japan's most advanced electric aircraft testbeds, operated by the Joint Research Centre for Electric Architecture in Akita's state-of-the-art all-electric aircraft testbed.The deal will also support new training and skills pathways for future aviation engineers and technicians, backed by industry and academic partnerships.Stralis' proprietary hydrogen-electric system is six times lighter than existing fuel cell solutions, enabling hydrogen aircraft to fly ten times further than battery-electric alternatives, at half the cost of fossil fuel-powered planes.The signing took place during a dedicated International Education, Research and Innovation Showcase hosted by Minister Bates at the Australia Pavilion, with Queensland as a Gold Partner of EXPO 2025."I'm extremely excited to begin our collaboration with this world class team and facility in Akita," said Bob Criner, Co-Founder and CEO of Stralis Aircraft."Japan has been a global leader in aerospace and hydrogen innovation for decades. This partnership will accelerate our hydrogen aircraft technology development and facilitate skills and knowledge exchange between our organisations."It will also allow Stralis to create cutting-edge research and innovation jobs in Queensland, where our workforce is prepared to manufacture and export advanced aircraft technology in the future.""We are pleased to sign this MoU with Stralis," said Junichi Sakaki, Director, Joint Research Center for Electric Architecture, Akita University / Akita Prefectural University."This collaboration in aircraft system electrification, using our testing facilities in Akita, represents a meaningful step in international technological cooperation. We look forward to contributing to both talent development and a more sustainable future."Supported by Trade and Investment Queensland (TIQ) Japan, Strali has been in high-level discussions with Japanese aerospace firms aligned with Japan's Ministry of Economy, Trade and Industry (METI) and its 2035 target to commercialise decarbonised passenger aircraft.Stralis is also planning to fly its Bonanza A36 hydrogen-electric demonstration aircraft in Japan in late 2026, showcasing the commercial and environmental viability of its technology.This agreement adds momentum to Queensland's broader trade mission in Japan, which is focused on expanding partnerships in International Education, Research and Innovation, advanced manufacturing, and the Queensland–Japan Trade and Investment Strategy 2025-2028, released this July, which places innovation-led collaboration at the core of the Queensland–Japan relationship.Contact:Minister Bates' Media Contact: Illka Gobius, Pinpont PR, illka@pinpointpr.sk Stralis Media Contact: https://stralis.aeroDr Emma Whittlesea, Stralis, Head of Partnerships, ew@stralis.aeroBob Criner, Co-Founder & CEO, Stralis Aircraft, bc@stralis.aero   Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, August 1, 2025 - (JCN Newswire via SeaPRwire.com) - Hitachi, Ltd. (TSE:6501, “Hitachi”) and, its subsidiary, Hitachi Global Life Solutions, Inc. (“Hitachi GLS”), announced that they have completed the capital reorganization of their air conditioning joint venture, based on the agreement signed on July 23, 2024*1. Under this reorganization, Hitachi GLS transferred all of its shares in Johnson Controls-Hitachi Air Conditioning Holding (UK) Ltd. (“JCH”), a joint venture with Johnson Controls International plc(“JCI”), to Robert Bosch GmbH (“Bosch”)*2, and has completed the acquisition of the Shimizu Factory, which had been owned by JCH and served as its development and production base for commercial air conditioning equipment in Japan*3Going forward, Hitachi GLS will accelerate a global expansion of Hitachi-branded air conditioning products through Bosch Home Comfort Group (“Bosch HC”), Bosch’s HVAC*4 business unit. Meanwhile, Hitachi will utilize its domain knowledge acquired through the Shimizu Factory to further strengthen its “Lumada 3.0” green cooling solutions through “One Hitachi” by combining the large installed base of HVAC units, AI, and digital capabilities to accelerate the expansion into growing markets such as green buildings and data centers. This will contribute to the realization of a harmonized society where environment, well being, and economic growth are in balance, as envisioned in Inspire 2027, Hitachi Group’s new management plan.Aim of the Hitachi Group1. Strengthening the Global Expansion of Hitachi-branded Air Conditioning Products, and an Expansion of the Partnership with BoschUnder a brand license agreement with Bosch HC, Hitachi GLS will accelerate global expansion by utilizing Bosch’s global footprint centered in Europe and promoting sales of highly competitive, Hitachi-branded residential air conditioning products in the residential and light commercial HVAC markets in the US and Asia. Also, further expansion of the partnership with Bosch will be achieved by incorporating Lumada solutions in products.2. Collaborating as One Hitachi to Accelerate the Deployment of Green Cooling Solutions in Growth Markets With the acquisition of the Shimizu Factory, with its high technological capabilities, Hitachi GLS will integrate the development, manufacturing, sales, and maintenance services for the commercial air conditioning business in Japan to develop competitive products tailored to market needs. Also, Hitachi GLS will further enhance its Lumada solutions, such as “exiida*5”, which leverages data from the large installed-base of HVAC units and AI to support the stable operation of air-conditioning units.Hitachi will expand green cooling solutions that combine its extensive installed base of mission critical products with AI-enabled digital services as use cases of “HMAX for Industry” in growing industrial markets such as green buildings, biopharma, food, and semiconductor manufacturing facilities. In addition, Hitachi will accelerate the “One Hitachi” total solutions including air conditioning and cooling technologies in data centers, designated by the Strategic SIB*6 Business Unit as a strategic business area.To ensure continued distribution of “Shirokumakun*7” series residential air conditioning products for the Japanese market, the Tochigi Factory*8 of JCH which was acquired by Bosch HC in the transaction, will retain development and manufacturing operations, while Hitachi GLS will remain responsible for sales and aftermarket services.The purchase price of the 40% stake in JCH held by Hitachi GLS is approximately USD 1.46 billion (approximately JPY 211 billion*9). As a result, Hitachi plans to record business reorganization income, etc. of approximately JPY 154 billion as other income, etc. in its consolidated financial statements for the fiscal year ending March 2026. Please note that the final purchase price will be determined separately after accounting for all necessary adjustments. Hitachi will utilize the proceeds from this share transfer for its growth investments and shareholder returns, aiming to enhance its capital efficiency and further increase corporate value.Comments from Brice Koch — Executive Vice President and Executive Officer, Head of Connective Industries Business of Hitachi, Ltd. We are very pleased to have completed this capital reorganization which will further accelerate the growth of our HVAC business. Under Inspire 2027, Hitachi’s new Management Plan, we are committed to realize a harmonized society, where environment, well being and economic growth are in balance. We aim to drive global expansion of business, as we promote “Lumada 3.0” digital services as “HMAX for Industry” with “One Hitachi”, leveraging our AI capabilities, as well as large installed base of mission-critical products including industrial HVAC units.Comments from Noriharu Amiya — Senior Vice President and Executive Officer, COO of Connective Industries, CEO of Urban Systems Business Unit of Hitachi, Ltd. / Chairman of Hitachi Building Systems Co., Ltd. We will strengthen collaboration between our building systems and air conditioning businesses to expand the value of green cooling solutions into mission-critical areas such as green data centers, biopharmaceutical facilities requiring extremely high air quality, and manufacturing facilities for food and semiconductors, there by achieving further growth. Leveraging Hitachi's strengths in IT, OT (operational technology), and products, we will expand value through the building IoT solutions including the air conditioning IoT solution “exiida” and the building IoT solution “BuilMirai*10,” accelerating the deployment of green cooling solutions with “One Hitachi”. Through these initiatives, we will provide new value to “people, buildings, and society” and contribute to the realization of a harmonized society.Comments from Hideki Osumi — President of Hitachi Global Life Solutions, Inc. We are filled with excitement about taking on new challenges together with our new colleagues from the Shimizu Factory and striving for sustainable growth as the new Hitachi GLS. Hitachi GLS and Bosch will strengthen their partnership and promote the global expansion of Hitachi-branded air conditioning products. In the commercial air conditioning business in Japan, where a new business structure has been established, we will provide high value-added solutions tailored to market needs and contribute to the realization of a sustainable society by reducing environmental impact and improving energy efficiency. We would like to express our deepest gratitude to all those involved in the completion of this reorganization.*1 Please see the news release “Hitachi to Announce Capital Reorganization of Air Conditioning Joint Venture” issued on July 23, 2024. (https://www.hitachi.com/New/cnews/month/2024/07/240723.html)*2 Hitachi GLS and JCI, which held 40% and 60% of JCH shares respectively, sold their entire stake to Bosch, which now owns 100% of JCH.*3 On April 1, 2025, through a company split, the business of the Shimizu Factory was transferred from Hitachi Johnson Controls Air Conditioning, Inc. (the Japanese subsidiary of JCH) to a newly established company, Hitachi Air Conditioning Shimizu, Inc., which will be merged with Hitachi GLS later this year.*4 HVAC stands for Heating, Ventilation, and Air Conditioning.*5 “exiida” is a registered trademark of Hitachi Global Life Solutions, Inc. in Japan.*6 Social Innovation Business*7 “Shirokumakun” is a registered trademark of Hitachi-Johnson Controls Air Conditioning Inc. in Japan.*8 Hitachi-Johnson Controls Air Conditioning, Inc Tochigi Factory, a Japanese subsidiary of JCH. The company’s name is scheduled to change in the future.*9 Exchange rate used is USD 1.00 = JPY 144.*10 “BuilMirai” is a registered trademark of Hitachi, Ltd.About Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT(Operational Technology) and products, Hitachi contributes to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates globally in four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – and the Strategic SIB Business Unit for new growth businesses. With Lumada at its core, Hitachi generates value from integrating data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2024(ended March 31, 2025) totaled 9,783.3 billion yen, with 618 consolidated subsidiaries and approximately 280,000 employees worldwide. Visit us at www.hitachi.comAbout Hitachi Global Life Solutions, Inc.Hitachi Global Life Solutions, Inc. operates under the purpose:"To bring a smile to the life of each individual. To create a future that is kind to people and society. We will bring happiness to the world through innovations that open up the future."Hitachi GLS provides home appliances, air conditioning equipment, facility systems, as well as engineering and maintenance services. Hitachi GLS is focused on the Lumada business, which creates value from data generated by its footprint and products. Through “One Hitachi”, Hitachi GLS contributes to realizing both Work Transformation and Green Transformation. Visit us at corp.hitachi-gls.co.jp Copyright 2025 JCN Newswire via SeaPRwire.com.

From left to right: Takao Kato, President & CEO of Mitsubishi Motors; Satoshi Nakano, President & CEO of MMFP; Sanjiv Vohra, President & CEO of SBC.MANILA, August 1, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Motors Finance Philippines Inc. (hereafter, MMFP), the joint venture between Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) and Security Bank Corporation (hereafter, Security Bank), officially launched its operations today. Under the brand "Mitsubishi Motors Finance powered by Security Bank," MMFP started operations at five Mitsubishi Motors dealerships in April and now offer financing solutions across all 67 Mitsubishi Motors dealerships nationwide.This nationwide rollout marks a key milestone in Mitsubishi Motors' mid-term business plan, Challenge 2025, which positions ASEAN as a core growth region—with MMFP playing a strategic role in driving that expansion in the Philippines. With a steadily growing population and strong economic fundamentals, the Philippine automotive market is on a clear growth path. In FY2024, Mitsubishi Motors sold 91,639 units locally—a 12% increase year-on-year—cementing the Philippines as one of its top ASEAN markets with 19.5% market share.Driving growth through collaborationWith many new car buyers in the Philippines relying on financing, sales financing plays a critical role in enabling car ownership. By bringing together Mitsubishi Motors' robust market presence and Security Bank's financial expertise, MMFP is committed to driving the continued growth of Mitsubishi Motors' sales in the Philippines."The official launch of MMFP marks a significant milestone in Mitsubishi Motors' long-standing journey in the Philippines," said Takao Kato, President & CEO of Mitsubishi Motors. "We remain committed to the country as one of our most important markets. Through collaboration with MMFP in financing services and Mitsubishi Motors Philippines Corporation in local production and sales, we will continue to grow and serve our customers with excellence.""The official launch of MMFP is a milestone that underscores the strengths of our strategic partnerships— with Mitsubishi Motors and Security Bank." said Sanjiv Vohra, President & CEO of SBC. "We're uniting global expertise with local insight to make car ownership more accessible for Filipinos. Reflecting the Bank's commitment to Better Banking, MMFP delivers innovative, reliable financing solutions that empower customers and elevate their quality of life.""Today marks a key milestone for MMFP as we launch nationwide." said Satoshi Nakano, President & CEO of MMFP. "As a joint venture between Mitsubishi Motors and Security Bank, MMFP brings together market leadership and financial expertise to offer accessible, reliable financing. Our shared vision is to enrich Filipino lives by making car ownership more attainable and supporting Mitsubishi Motors' continued growth in the country."About Mitsubishi Motors Finance Philippines Inc.EstablishmentJanuary 21, 2025President & CEOSatoshi NakanoLocationMakati City, PhilippinesShareholdersMitsubishi Motors Corporation 51%Security Bank Corporation 49%BusinessProvision of financing services and products to Mitsubishi Motors dealerships in the PhilippinesOfficial Websitehttps://mmfp.ph About Mitsubishi Motors CorporationMitsubishi Motors Corporation (TSE:7211) — a member of the Alliance with Renault and Nissan — is a global automobile company based in Tokyo, Japan, which has about 28,000 employees and a global footprint with production facilities in Japan and the ASEAN region. Mitsubishi Motors has a competitive edge in SUVs, pickup trucks and plug-in hybrid electric vehicles, and appeals to ambitious drivers willing to challenge convention and embrace innovation. Since the production of our first vehicle more than a century ago, Mitsubishi Motors has been a leader in electrification — launched the i-MiEV, the world's first mass-produced electric vehicle in 2009, followed by the Outlander PHEV, the world's first plug-in hybrid electric SUV in 2013. With a target of increasing the sales ratio of electrified vehicles to 100% by 2035, Mitsubishi Motors will deliver models that embody Mitsubishi Motors-ness and contribute to the realization of a carbon-neutral society. For more information on Mitsubishi Motors, please visit the company's website at https://www.mitsubishi-motors.com/en/About Security Bank CorporationEstablished in 1951, Security Bank is one of the Philippines' leading universal banks and is publicly listed with the Philippine Stock Exchange (PSE:SECB) in 1995. The Bank's core businesses are retail, corporate, commercial, and business (MSME) banking, offering a wide range of services including lending, leasing, foreign exchange, stock brokerage, investment banking, and asset management.Security Bank differentiates itself from other banks as a strong, domestic, independent bank that delivers a superior customer experience in line with its brand promise of Better Banking. This is based on a deep understanding of customer needs, providing solutions in a professional, hassle-free, personalized, and timely manner. The Bank's strategic alliance with MUFG Bank, Ltd., Japan's largest bank, provides its customers with access to a broad global network.The Bank has been recognized by international and local organizations for its constant product innovation, market leadership, and best-in-class management practices.For more information, visit www.securitybank.com.Security Bank Corporation is regulated by the Bangko Sentral ng Pilipinas www.bsp.gov.ph Copyright 2025 JCN Newswire via SeaPRwire.com.

ISTANBUL, Turkiye, August 1, 2025 - (JCN Newswire via SeaPRwire.com) – Honda Turkiye A.S. (HTR) has decided to establish a new motorcycle factory in Aliaga, izmir, aimed at supporting growth in the motorcycle market and boosting global motorcycle sales.The COVID-19 pandemic has led to an increased demand for personal transportation and commercial use, such as delivery services, driving significant growth in the Turkish motorcycle market. As a result, Honda Turkiye set a new sales record in 2024 with annual sales reaching 162,000 motorcycles.Production is scheduled to begin in mid-2026. Initially, the plant will operate with an annual capacity of 100,000 motorcycles, with plans to increase production capacity to 200,000 units in the future. The total investment amount for the facility including machinery and equipment is approximately 20 million USD. The plant is expected to create employment opportunities for around 300 people.With this new investment, Honda Turkiye aims to strengthen local production activities and contribute to the development of the motorcycle industry in Turkiye by providing high-quality, affordable, and attractive products. About Honda Turkiye A.S.Established :February 1992Headquarter :Maltepe, IstanbulCapital :180 million TLOwnership :Honda Motor Europe Ltd. (100%)President :Satoru YamadaBusiness Activities :Import and sales of motorcycles, automobiles, and partsNumber of Employees :Approximately 160 (as of July 2025)   Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, Japan, August 1, 2025 - (JCN Newswire via SeaPRwire.com) – Honda Motor Co., Ltd. (Honda) has started a demonstration project jointly with Tokuyama Corporation (Tokuyama) and Mitsubishi Corporation (MC), to operate a data center using by-product hydrogen and a stationary fuel cell (FC) power station designed to reuse FC systems from fuel cell electric vehicles (FCEVs). The companies today held an opening ceremony at the demonstration site located in Shunan City, Yamaguchi Prefecture, Japan. Honda FC power station to be used for this demonstration projectThe three companies have been discussing and preparing for the launch of the demonstration project since June 2023, when this project was proposed to and adopted by the New Energy and Industrial Technology Development Organization (NEDO) as one of the projects for the “Development of Technologies for Realizing a Hydrogen Society / Development of Technologies for Regional Hydrogen Utilization.”In this demonstration project, a stationary FC power station that Honda has developed based on the assumption of reusing fuel cells recovered from FCEVs utilizes by-product hydrogen produced by Tokuyama’s salt water electrolysis business to generate electricity and supply the electricity to a distributed data center operated by MC, at the demonstration site located in Shunan City, Yamaguchi Prefecture, Japan.Through this demonstration project, the three companies will explore the potential of reusing automotive FC systems for stationary FC power station applications, and verify the possibility of contributing to 1) a reduction in the economic burden on customers who will install and operate stationary FC power stations and 2) the decarbonization of electric power, through effective use of FC systems, which are expected to see broader adoption in the future.A further increase in power demand for data centers is expected in the long run due to the advancement of technologies that require large-volume data processing, such as generative AI and automated driving. In the face of this market environment, by utilizing 1) by-product hydrogen, which can be produced/supplied stably with low carbon emissions, and 2) FCs designed to be reused, to supply electricity to distributed data centers, the three companies will strive to contribute to the “green transformation” (GX) of data centers and the digital transformation (DX) of municipalities and local businesses. Multiple patterns of power supply operations to be demonstratedIn this demonstration, electricity from multiple sources, such as 1) a stationary FC power station that utilizes by-product hydrogen, 2) the power grid, 3) stationary batteries (BESS*¹), and 4) renewable energy sources will be combined to verify more efficient and optimal power configuration for different patterns of operation.The following specific patterns of stationary FC power station utilization, based on various possible scenarios, will be demonstrated by switching among these operation patterns via an Energy Management System (EMS):1) Use as a backup power source2) Use as an off-grid primary power s1ource3) Use for peak shaving of grid electricity consumption4) Use for grid supply-demand balancing, including supplying electricity back to the gridIn addition to verifying the practicality and business viability of stationary FC power station operation, a wide range of potential applications will be explored through this demonstration project. *1 BESS: Battery Energy Storage System*2 Peak shaving: Reducing electricity consumption during peak demand periodsAbout Honda Stationary Fuel Cell Power StationHonda was one of the first companies to focus on the potential of hydrogen toward the realization of a carbon-neutral society and has been conducting research and development of hydrogen technologies and FCEVs for more than 30 years. Working toward the realization of carbon neutrality for all products and corporate activities Honda is involved in by 2050, Honda has identified four core domains for its fuel cell system application – fuel cell electric vehicles (FCEVs), commercial vehicles, stationary power station and construction machinery – and has been working to further expand opportunities for its hydrogen business.The Honda stationary FC power station is a stationary power storage system designed to supply clean, hydrogen-derived electricity to large-scale facilities such as factories and other business operations. The stationary FC power station being used in this demonstration project utilizes fuel cells used for a Honda CR-V e:FCEV fuel cell electric vehicle.The Honda stationary FC power station is capable of supplying electricity to meet the  maximum amount of electricity consumption by the customer in accordance with their needs. Moreover, the compact size of the unit achieved by the optimization of the cooling system and internal layout enables flexible installation options to accommodate the conditions of the customer’s installation site. In addition, the Honda stationary FC power station is designed to achieve high responsiveness, aiming to begin power supply within 10 seconds of startup, to serve as a reliable backup power source in case of an emergency.Through its stationary FC power station, Honda will supply electricity that accommodates the various power needs of customers, while also contributing to the decarbonization efforts of each customer by providing comprehensive support for the entire process—from installation to after-sales services.  For more details, please visit:https://global.honda/content/dam/site/global-en/newsroom-new/cq_img/news/2025/08/c250801aeng/c250801aeng.pdf  Copyright 2025 JCN Newswire via SeaPRwire.com.

KARIYA, JAPAN, August 1, 2025 - (JCN Newswire via SeaPRwire.com) - BluE Nexus Corporation (headquartered in Anjo, Aichi; Hidetoshi Uchiyama, president; hereinafter “BluE”), AISIN Corporation (headquartered in Kariya, Aichi; Moritaka Yoshida, president; hereinafter “AISIN”), and DENSO CORPORATION (headquartered in Kariya, Aichi; Shinnosuke Hayashi, president; hereinafter “DENSO”) are proud to announce that, the eAxle jointly developed by the three companies has been installed in Isuzu's first battery electric vehicle (BEV) pickup, D-MAX EV, which went into production in April 2025.The newly installed product combines the newly developed eAxle front and rear with a full-time *4WD system, contributing to both the tough basic performance required for pickup trucks (durability/loading and towing performance/rugged road drivability) and the linear acceleration and low noise and vibration characteristic of BEVs. The BEV is a 4WD system with a low-noise and low-vibration engine.As D-MAX EVs are gradually expanded globally, starting with shipments to major European countries and gradually adapting to market characteristics and customer needs, this product will also provide high-performance drive solutions around the world.Going forward, BluE, AISIN, and DENSO will continue to provide valuable technologies and products by leveraging their respective strengths and know-how. In addition, through BluE, we will contribute to the realization of a carbon-neutral society by having our products installed in all types of electric vehicles.*Full-time 4WD is a drive system that transmits power to both the front and rear wheels at all times, regardless of road conditions, including off-road and on-road driving.About BluE Nexus,“BluE”BluE is an electrification system and electric drive module development and sales company established in April 2019. BluE aims to meet the needs of customers worldwide and contribute to the further development and popularization of electrified vehicles and the realization of carbon neutrality in society.About DENSO CORPORATIONGlobally headquartered in Kariya, Japan, DENSO is a 7,161.8 billion yen leading mobility supplier that develops advanced technology and components for nearly every vehicle make and model on the road today. With manufacturing at its core, DENSO invests in around 180 facilities worldwide to provide opportunities for rewarding careers and to produce cutting-edge electrification, powertrain, thermal and mobility electronics products, among others, that change how the world moves. In developing such solutions, the company’s 158,000 global employees are paving the way to a mobility future that improves lives, eliminates traffic accidents, and preserves the environment. DENSO spent around 8.6 percent of its global consolidated sales on research and development in the fiscal year ending March 31, 2025. For more information about DENSO’s operations worldwide, visit https://www.denso.com/global  Copyright 2025 JCN Newswire via SeaPRwire.com.

Kawasaki, Japan, August 1, 2025 - (JCN Newswire via SeaPRwire.com) - Fujitsu today announced that it has started research and development towards a superconducting quantum computer with a capacity exceeding 10,000 qubits. Construction is slated for completion in fiscal 2030.The new superconducting quantum computer will operate with 250 logical qubits and will utilize Fujitsu's innovative "STAR architecture," an early-stage fault-tolerant quantum computing (early-FTQC) architecture also developed by the company. Fujitsu aims to make practical quantum computing possible, particularly in areas like materials science where complex simulations can unlock ground breaking discoveries, and to this end will focus on advancing key scaling technologies across various technical domains.As part of this effort, Fujitsu has been selected as an implementing party for the "Research and Development Project of the Enhanced Infrastructures for Post-5G Information and Communication Systems" [1], publicly solicited by the NEDO (New Energy and Industrial Technology Development Organization). Fujitsu will be contributing to the thematic area of advancing the development of quantum computers towards industrialization. The project will be promoted through joint research with Japan’s National Institute of Advanced Industrial Science and Technology (AIST) and RIKEN, and will run until fiscal year 2027.Fujitsu is committed to driving forward the development of practical and industrialized quantum computing solutions. After this 10,000-qubit machine is built, Fujitsu will further pursue advanced research initiatives targeting the integration of superconducting and diamond spin-based qubits from fiscal 2030 and aims to realize a 1,000 logical qubit machine in fiscal 2035 while considering the possibility of multiple interconnected quantum bit-chips.Vivek Mahajan, Corporate Executive Officer, Corporate Vice President, CTO, in charge of System Platform, Fujitsu Limited, comments:"Fujitsu is already recognized as a world leader in quantum computing across a broad spectrum, from software to hardware. This project, led by NEDO, will contribute significantly to Fujitsu’s goal of further developing a Made-in-Japan fault tolerant superconducting quantum computer. We would also be aiming to combine superconducting quantum computing with diamond spin technology as part of our roadmap. By realizing 250 logical qubits in fiscal 2030 and 1,000 logical qubits in fiscal 2035, Fujitsu is committed to leading the path forward globally in the field of quantum computing. Additionally, Fujitsu will be developing the next generation of its HPC platform, using its FUJITSU-MONAKA processor line, which will also power FugakuNEXT. Fujitsu will further integrate its platforms for high-performance and quantum computing to offer a comprehensive computing platform to our customers."Technology development focus areasFujitsu’s research efforts will focus on developing the following scaling technologies.1. High-throughput, high-precision qubit manufacturing technology:Improvement of the manufacturing precision of Josephson Junctions, critical components of superconducting qubits which minimize frequency variations.2. Chip-to-chip interconnect technology:Development of wiring and packaging technologies to enable the interconnection of multiple qubit chips, facilitating the creation of larger quantum processors.3. High-density packaging and low-cost qubit control:Addressing the challenges associated with cryogenic cooling and control systems, including the development of techniques to reduce component count and heat dissipation.4. Decoding technology for quantum error correction:Development of algorithms and system designs for decoding measurement data and correcting errors in quantum computations.BackgroundThe world faces increasingly complex challenges that demand computational power beyond the reach of traditional computers. Quantum computers offer the promise of tackling these previously intractable problems, driving significant advancements across numerous fields. While a fully fault-tolerant quantum computer with 1 million qubits of processing power is considered the ultimate goal, Fujitsu is focused on delivering practical solutions in the near term.Fujitsu's commitment to quantum computing is underscored by its ongoing R&D efforts. In August 2024, in collaboration with the University of Osaka, Fujitsu unveiled its STAR architecture, a highly efficient quantum computing architecture based on phase rotation gates. This architecture paves the way for early-FTQC systems capable of outperforming conventional computers with only 60,000 qubits [2]. On the hardware front, the RIKEN RQC-Fujitsu Collaboration Center, established in 2021 with RIKEN, has already yielded a 64-qubit superconducting quantum computer in October 2023, followed by a world-leading 256-qubit system in April 2025 [3].Scaling to even larger systems requires overcoming challenges such as maintaining high fidelity across multiple interconnected qubit chips and achieving greater integration of components and wiring within dilution refrigerators. In addition to its superconducting approach, Fujitsu is also exploring the potential of diamond spin-based qubits, which use light for qubit connectivity. Fujitsu is conducting research in this area in collaboration with Delft University of Technology and QuTech, a leading quantum technology research institute, which has resulted in the successful creation of highly accurate and controllable qubits.[1] Research and Development Project of the Enhanced Infrastructures for Post-5G Information and Communication Systems[2] In simulations using 60,000 qubits, the STAR architecture can execute material energy estimation calculations which would take 5 years on conventional computers in about 10 hours.[3] One of the world's largest superconducting quantum computers available to external users (as of April 2025, according to Fujitsu).About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, July 31, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the global revenue(pre-audit basis) of the anti-amyloid-beta protofibril antibody “LEQEMBI®” (generic name: lecanemab) was JPY 23.1 billion for the first quarter of fiscal year 2025 (April 1, 2025 – June 30, 2025). By major markets, revenue came to JPY 9.1 billion in the United States, JPY 5.5 billion in Japan, and JPY 7.7 billion in Chinadue to increasing demand and stock piling by distributors (estimated at JPY 5.3 billion) in response to the risk of tariffs. This information is being disclosed in conjunction with today's announcement of the financial results for the second quarter of 2025 by Biogen Inc. (Headquarters: Cambridge, Massachusetts). Eisai’s financial results for the first quarter of fiscal year 2025, including details of LEQEMBI’s revenue, will be disclosed in Eisai's financial disclosure scheduled for August 5, 2025.Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen Inc. co-commercializing and co-promoting the product and Eisai having final decision-making authority. Copyright 2025 JCN Newswire via SeaPRwire.com.

Takamatsu, Kagawa, July 23, 2025 - (JCN Newswire via SeaPRwire.com) - Sharp reached an agreement with Aoi Electronics Co., Ltd. (Headquarters / Takamatsu City, Kagawa Prefecture, President & CEO / Kazuhiro Kinoshita; hereinafter "Aoi Electronics") on the transfer of Sharp Mie Plant No.2 and part of the land at Sharp Mie Base.Under its asset-light initiative in devices business and to transfer its structure centering its Brand business, Sharp is promoting the utilization of underutilized and unused factories, as well as business development through collaboration with other companies. This agreement is part of such initiative and corresponds to the consideration of transferring the Mie Plant No.2 mentioned in the news release dated March 31, 2025.Through Sharp Display Technology Corporation, Sharp’s subsidiary in charge of small and medium size LCD business, Sharp will collaborate with Aoi Electronics on the early start-up of their production line in the factories they bought.*Property for Transfer(1) Sharp Mie Plant No. 2 (Building)・Location: Gosana, Taki-cho, Taki-gun, Mie Prefecture・Total Floor Area: Approx. 54,000 square meters　(including production area: approx. 20,000 square meters)・Contract Date/ Delivery Date: July 31, 2025(2) Land　・Location: Gosana, Taki-cho, Taki-gun, Mie Prefecture・Land Area: Approx. 58,000 square meters (Land for Sharp Mie Plant No.1 and No.2)・Contract Date: July 31, 2025・Delivery Date: End of December, 2025 (plan) Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, July 31, 2025 - (JCN Newswire via SeaPRwire.com) - TANAKA PRECIOUS METAL GROUP Co., Ltd. (Headquarters: Chuo-ku, Tokyo; Group CEO: Koichiro Tanaka) has decided to enter into a business partnership with JEPLAN, INC. (Headquarters: Kawasaki City, Kanagawa; Representative Director, President, and Chief Executive Officer: Masaki Takao; hereinafter “JEPLAN”) to reduce CO₂ emissions and promote the recycling organic materials in the precious metal recovery processes of TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd., a company engaged in precious metals business.This initiative represents a collaboration between TANAKA, committed to advancing a circular economy in the precious metals field, and JEPLAN, which has been pursuing similar goals in the plastics field, with both companies aiming to achieve a decarbonized, circular society.TANAKA’s Initiatives Thus Far for Realizing a Circular SocietySince its founding in 1885, TANAKA has been a leader in the precious metals industry, actively engaged in recycling these limited and valuable resources. Among the process waste materials received from customers who request recycling, those containing organic materials (plastics) as main components with precious metals attached or adsorbed have traditionally been processed through incineration to remove the organic materials, with precious metals then recovered from the ash left behind.While this incineration process has addressed the removal of environmentally regulated substances, the reduction of CO₂ generated during the combustion of organic materials has become a major challenge in realizing a decarbonized society.Transforming the Precious Metal Recovery Process Through a Business Partnership with JEPLANJEPLAN has established proprietary chemical recycling technology for polyethylene terephthalate, a type of plastic. To address the aforementioned CO₂ emissions issue, TANAKA is considering using chemical recycling in the future, in addition to the conventional precious metal recovery process through incineration. This initiative is being explored through a business partnership with JEPLAN. The materials targeted for chemical processing include plastics such as syringes and wiping cloths. CO₂ emissions from the targeted precious metal recovery process are expected to be reduced to approximately 10% of conventional levels.In addition, this process enables not only precious metal recovery, but also plastic regeneration, with TANAKA and JEPLAN each contributing to the realization of a decarbonized, circular society through their respective areas of expertise.JEPLAN, INC. ( https://www.jeplan.co.jp/en/ )Representative: Masaki Takao, Representative Director, President, and Chief Executive OfficerEstablished: January 2007Main Business: Business based and related to PET chemical recycling technology (for PET bottles, polyester), etc.The JEPLAN Group aims to realize a circular economy with its mission of "We circulate our world." We use our proprietary PET chemical recycling technology to break down waste PET (PET bottles, polyester fibers, etc.) into molecules and remove impurities, regenerating it into recycled materials of the same quality as petroleum-derived materials. Through our recycling efforts using this proprietary technology, we are realizing the recycling of limited resources and contributing to the reduction of CO₂ emissions.The JEPLAN Group operates PET chemical recycling plants at two locations, PET REFINE TECHNOLOGY CO., LTD. (Kawasaki City, Kanagawa Prefecture, for PET bottles) and Kitakyushu Hibikinada Plant (Kitakyushu City, Fukuoka Prefecture, for polyester fibers), and is also promoting technology licensing in Japan and overseas.About TANAKASince its foundation in 1885, TANAKA has built a portfolio of products to support a diversified range of business uses focused on precious metals. TANAKA is a leader in Japan regarding the volume of precious metals it handles. Over many years, TANAKA has manufactured and sold precious metal products for industry and provided precious metals in such forms as jewelry and assets. As precious metals specialists, all Group companies in Japan and worldwide collaborate on manufacturing, sales, and technology development to offer a full range of products and services. With 5,591 employees, the group’s consolidated net sales for the fiscal year ending December 2024, was 846.9 billion yen.TANAKA Industrial Precious Metal Materials Portalhttps://tanaka-preciousmetals.comProduct inquiriesTANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-on-industrial-products/Press inquiriesTANAKA PRECIOUS METAL GROUP Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-for-media/Press release: https://www.acnnewswire.com/docs/files/20250731.pdf   Copyright 2025 JCN Newswire via SeaPRwire.com.

Developing dual-use UAVs for civil and defense applicationsAutomating the transport of heavy cargo with MHI's multi-purpose medium-sized UAVAccelerating the transport of medications using a VTOL (vertical take-off and landing) UAV capable of flying long distances at high speedTOKYO, July 31, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) participated in a practical training exercise held on July 17 at the Japan Ground Self-Defense Force (JGSDF) Asaka Garrison (Nerima-ku, Tokyo), aimed at improving response capabilities in the event of an earthquake centered on the Tokyo metropolitan area. The training was conducted by the JGSDF Eastern Army in cooperation with local governments, with MHI joining at the request of the Japan UAS Industrial Development Association (JUIDA). MHI conducted training to transport relief supplies to isolated disaster victims using its medium-sized multirotor uncrewed aerial vehicle (hereinafter "medium-sized UAV") currently being developed by its Commercial Aviation Systems division, and the VTOL (vertical take-off and landing) UAV being developed by the Integrated Defense & Space Systems division.The medium-sized UAV is being developed for a variety of purposes, such as transporting relief supplies in the event of a disaster, providing logistics support to remote islands and mountainous areas, and conveying materials for construction work on power transmission towers. It has conveyance functionality with enhanced wind resistance during takeoff and cruising, and an automatic unloading function that allows the cargo to be lowered at the destination with a winch from a hovering state without having to land. For this exercise, MHI conducted a loading demonstration of relief supplies, and a flight demonstration. Going forward, MHI will pursue further functional improvements such as incorporation of satellite communication capabilities, and extension of the cruising range with a hybrid power system.(Note)The VTOL UAV is being developed for the purpose of quickly delivering relief supplies to remote islands and ships in transit. It is capable of high speed flight over long distances of up to 1,000 kilometers, and can take off and land even in places without runways. For this exercise, MHI took advantage of the maneuverability and vertical take-off and landing capabilities of the VTOL UAV to demonstrate quick delivery of medicines to disaster areas.MHI will continue to pursue the development of dual-use UAVs with consideration for both civil and defense applications, and through their use, work to provide solutions for various societal challenges.Medium-sized UAV used during training for the transport of relief suppliesVTOL UAV used during training for the transport of relief suppliesNote: Using an engine to generate electricity.Specifications of the Medium-Sized UAVPayload (maximum): 200kgCruising range: 15km (battery type), 200km (hybrid type under development)Dimensions: Overall length approx. 6mMotive power: Battery type, Hybrid type (under development)Ease of transport: Can be transported by truck to takeoff/landing pointsAdditional equipment for demonstration testing: Automatic unloading system using a winch, relief supplies transport containerSpecifications of the VTOL UAVPayload (maximum): 5kgCruising range: 1,000kmDimensions: Overall length approx. 2.4m, main wingspan 3.4mMotive power: For fixed-wing propulsion: EngineFor multicopter: Electric motorsAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2025 JCN Newswire via SeaPRwire.com.

- Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer’s Disease- 56% of Patients with Low Tau Continued to Demonstrate Improved Cognitive and Daily Living Function at Four YearsTOKYO and CAMBRIDGE, Mass., July 31, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”)and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher,“Biogen”) announced today that the latest findings demonstrating the benefits of continuous treatment with lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer’s disease (AD), were presented at the Alzheimer's Association International Conference(AAIC) 2025, held in Toronto, Canada, and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.Four Years of Lecanemab Therapy Helped Patients Slow the Progression of AD and Remain in the Early Stages of AD Longer Compared to AD’s Natural Course Clarity AD is a global Phase 3 placebo-controlled, double-blind, parallel-group, randomized study to evaluate lecanemab 10 mg/kg bi-weekly IV treatment of early Alzheimer's disease, which involved 1,795 patients(treatment group: 898, placebo group: 897). 95% of patients who completed the core study (18 months) chose to continue in the open-label extension study (OLE), with 478 patients still receiving treatment for four years. In the Clarity AD core study, the mean change from baseline between the lecanemab treated group and the placebo group after 18 months was -0.45 (P=0.00005) on the primary endpoint of CDR-SB global cognitive and functional scale.To provide context, a change from 0.5 to 1 on the Clinical Dementia Rating (CDR) score domains of Memory, Community Affairs and Home/Hobbies reflects a shift from mild impairment to loss of independence. This can affect a person’s ability to be left alone safely, recall recent events, participate in daily activities, manage household tasks, and engage in hobbies and intellectual interests.1,2Over three years of treatment, including both the core study and the OLE, data showed lecanemab demonstrate da reduction in cognitive decline—measured by CDR-SB—of 1.01 points compared to the expected decline observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI)** cohort. This benefit grew more pronounced after four years, with a reduction of 1.75 points. Similarly, when bench marked against the expected decline in the BioFINDER*** cohort, lecanemab showed a reduction of 1.40 points at three years and an even greater reduction of 2.17 points at the four years mark. For more details, please visit: https://www.eisai.com/news/2025/pdf/enews202554pdf.pdfMEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@Eisai.comBiogen Inc.Madeleine Shin+1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Tim Power+ 1-781-464-2442IR@biogen.com  Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO and CAMBRIDGE, Mass., July 31, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”)and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher,“Biogen”) announced today that results on investigational maintenance therapy with subcutaneous autoinjector (SCAI) of lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer’s disease (AD), were presented at the Alzheimer's Association International Conference(AAIC) 2025, held in Toronto, and virtually. Only lecanemab fights AD in two ways—targeting both protofibrils and plaque, which can impact tau accumulation downstream.Importance of Ongoing Treatment and SC Development ProgramDue to the reaccumulation of AD biomarkers and return to placebo rate of decline after therapy is stopped1, Eisai is investigating a new lecanemab SC maintenance treatment option following 18 months of IV therapy so patients can continue to fight this progressive, relentless disease.Clinical trials of lecanemab SC were conducted as a sub-study of the open-label extension (OLE) following the core Phase 3 Clarity AD study in individuals with early AD, to evaluate a range of doses administered by SC vial or autoinjector. Eisai has developed a SC-AI for maintenance therapy at a dose of 360 mg weekly and a500 mg SC-AI is being developed for initiation dosing. Similar Impact on Clinical Outcomes and Biomarkers with IV and SC DosingThe pharmacology (PK/PD), clinical (efficacy endpoints such as CDR-SB) and biomarker (amyloid PET and blood biomarkers) relationships established with extensive clinical data supported the FDA approval of IV maintenance therapy after the initial 18 months of treatment and support the investigational SC maintenance dose option.- Data supports that transitioning to a weekly 360 mg SC AI dose of lecanemab after 18 months of initiation dose (10 mg/kg IV biweekly) maintains clinical and biomarker benefits comparable to continued biweekly IV dosing.- Clinical and biomarker responses at 48 months with monthly IV maintenance dosing are similar to the responses with ongoing biweekly dosing whether patients are amyloid positive (>30 CL) or negative (<30 CL) at 18 months.- Data shows the 500 mg SC AI has equivalent exposure as the initial treatment regimen of 10mg/kg IV biweekly up to 18 months for amyloid removal, efficacy, and ARIA-E.Safety MattersThe safety profile of 360 mg weekly SC maintenance dosing was shown to be consistent with that of IV maintenance therapy, with <1% systemic injection/infusion reactions. Across all SC doses, the rate of systemic injection/infusion reactions is 1% compared to 26% with IV. The 360 mg SC maintenance dose was initiated after 18 months of IV treatment, beyond the high-risk period for ARIA. There were 0 cases of ARIA-E observed out of 49 treated with 360 mg SC weekly maintenance for a mean of 6 months.Study Participants Successfully Administered SC-AI and Found it Easy to UseTo optimize the safe and effective use of SC autoinjector (SC-AI), additional studies were conducted, including a human factors (HF) study and a tolerability assessment of the device.The HF Study involved 110 participants (63 early AD patients, 32 care partners, and 15 healthcare professionals: HCPs) to assess the appropriate administration of lecanemab SC-AI. Overall, 95% (104/110) of participants successfully administered the maintenance dose. The Autoinjector Device Acceptability Study involved 126 participants (25 early AD patients, 50 care partners, and 51 HCPs), to evaluate the device's ease of use, convenience and feasibility of administration. As an interim outcome, over 95% of participants reported that the SC-AI is easy to administer. They were highly satisfied with it and had no concerns about administration, even at home. Furthermore, all patients responded that they welcomed the introduction of SC-AI.These studies and evaluations of lecanemab SC-AI have demonstrated that the investigational SC-AI offers efficacy and safety comparable to IV administration with the potential to reduce the incidence of infusion site adverse events. From the perspective of patients and care partners, benefits included the ability to use the device at home, shortening treatment time, and to continue treatment without having to worry about visiting an infusion center. From the perspective of HCPs, they reported that the device has the potential to provide a new option for patients who are benefiting from lecanemab to continue the treatment. The SC formulation has the potential to reduce medical preparation and administration time related to IV therapy. These factors suggest that the SC AI may play an important role in continuing treatment for early AD.This release is based on the content of the presentations given at AAIC, "Featured Research Session #4-13-FRS-C: Lecanemab Subcutaneous Formulation for Maintenance Dosing: The Potential of a New and Convenient Option for Ongoing Treatment in Early Alzheimer’s Disease," held at 9:00 AM on Wednesday, July 30, and also includes some content from the Developing Topics session held at 8:00 AM on Sunday, July 27,entitled "Patient, Care Partner, and Health Care Professional Opinion of the Lecanemab Autoinjector for Subcutaneous Delivery in Early Alzheimer's Disease Patients."Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.* Protofibrils are thought to be the most toxic AB species that contribute to brain damage in AD and play a major role in the cognitive decline of this progressive and devastating disease. Protofibrils can cause neuronal and synaptic damage in the brain, which can subsequently adversely affect cognitive function through multiple mechanisms.1 The mechanism by which this occurs has been reported not only by increasing the formation of insoluble AB plaques, but also by directly damaging signaling between neurons and other cells. It is believed that reducing protofibrils may reduce neuronal damage and cognitive impairment, potentially preventing the progression of AD. 2For more details, please visit: https://www.eisai.com/news/2025/pdf/enews202553pdf.pdfMEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@Eisai.comBiogen Inc.Madeleine Shin+1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Tim Power+ 1-781-464-2442IR@biogen.com  Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO and CAMBRIDGE, Mass., July 31, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,“Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-AB protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways– targeting both amyloid plaque and protofibrils*, which can impact tau downstream.Lecanemab received traditional approval in the U.S. in July 2023 for the treatment of early Alzheimer's disease (AD). This retrospective study was conducted to investigate the actual state of real-world clinical treatment with lecanemabat 15 medical centers in the U.S., with a final report scheduled for late in the third quarter of Eisai’s fiscal year ending March 31, 2026. This presentation serves as an interim report as of July 1, 2025.Patient Baseline and Actual Treatment Situation The interim study collected information on 178 people living with early AD from nine US medical centers using a standardized case report format. The disease stage of the patients at baseline was mild cognitive impairment (MCI) due to AD in 57.6% and mild AD in 42.4%. The average age of the patients was 74.2 (±6.6) years, and the ratio of men to women was 44.6 to 55.4.The mean duration of lecanemab treatment was 375.4 days (± 182.8 days). The mean time from diagnosis to first treatment was 224.2 days (± 295.4 days) and the mean number of lecanemab treatments was 24.8 (± 11.5). At the time of case reporting, 87.4% of patients (152 patients) were continuing treatment with lecanemab. Adverse events leading to discontinuation of treatment included ARIA-E (ARIA-edema/exudation) in two patients (1.1%), ARIA-H(ARIA-cerebral microbleeds, cerebral hemorrhage and superficial hemosiderin deposition) in two patients (1.1%),and concomitant ARIA-E and ARIA-H in one patient (0.6%). Three patients (1.7%) discontinued due to adverse events other than ARIA. In addition, 11 patients (6.3%) reported discontinuing the treatment for personal reasons or at the discretion of their doctor or the individual.In this study, 83.6% of patients either remained at the same clinical stage or improved from mild dementia to MCI (stable: 76.9%, improvement: 6.7%). Additionally, at time of interim data cut, 86.7% of patients who had received 40 or more doses over 18 months remained stable or showed clinical improvement (stable: 66.7%,improvement: 20.0%:).Of the 178 patients, ARIA was observed in 23 (12.9%). 14 (7.9%) were observed to have ARIA-E, of which 12(6.7%) were asymptomatic. ARIA-H was present in 11 patients (6.2%), all of whom were asymptomatic. Infusion reactions were observed in four patients (2.2%). Additionally, no serious bleeding events or deaths were reported. Impact of APOE4 Status Of the 178 patients in this study, 12 were excluded with unknown status. Among the remaining 166 patients,30 (18.1%) were APOE 4 homozygotes, 84 (49.4%) were heterozygotes, 54 (32.5%) were non-carriers. Generally, the proportion of homozygotes among people with AD is thought to be 15% or more.The incidence of ARIA was 20.0%, 9.8% and 14.8% in homozygous carriers, heterozygous carriers and noncarriers, respectively (45.0%, 19.0% and 13.0% respectively in the Phase 3 Clarity AD 18-month core study). The incidence rate of ARIA-E and ARIA-H were 13.3% and 10.0%, respectively (32.6% and 39.0% in the Clarity AD core study), which is within the FDA-approved label range. The majority of ARIA cases (0.13%) were asymptomatic. The incidence of adverse events leading to discontinuation was 16.7% in homozygous carriers,2.4% in heterozygous carriers and 5.6% in non-carriers.73.3% of homozygote patients’ clinical stage remained stable or improved (stable: 66.6%, improved: 6.7%),88.0% of heterozygotes patients’ clinical stage remained stable or improved (stable: 83.0%, improved: 4.9%)and 85.2% of non-carrier patients’ clinical stage remained stable or improved (stable: 75.9%, improved: 9.3%).Utilization of Blood-Based Biomarkers (BBMs)BBMs are being developed in AD to identify brain AB pathology and are intended for use in prescreening (triage)and confirmatory diagnosis. Of the 178 patients in this study, 49 patients (27.5%) were diagnosed using BBMs. In some of these cases (11 patients, 6.1%), it was also used for confirmatory diagnosis. Data collected from clinical practices showed the volume of tests doubling every 4 to 8 months, with BBMs using p-tau217 growing most rapidly.Satisfaction with Lecanemab Treatment The results of a physician, patient and care partner lecanemab satisfaction survey was presented. The survey was based on questionnaires and interviews with nine U.S. physicians and evaluated treatment from multiple perspectives, including efficacy, safety and quality of life (QOL).In the physicians’ evaluation, the average satisfaction level for the treatment efficacy and safety (out of 10) was8.7. The scoring criteria included: cognition 8.1, daily function 8.1, behavioral/neuropsychiatric symptoms 7.9and QOL 8.0. The satisfaction level of the patients as assessed by physicians was 8.8, and that of the care partners was 8.2. These results highlight the favorable evaluation of lecanemab’s efficacy and safety in real world clinical practice and reinforce its therapeutic value.Note: Retrospective real-world studies can be very valuable in providing additional information to complement clinical trial data. However, there may have several limitations to keep in mind:Potential for BiasesData Completeness and ConsistencyData may be collected inconsistently since data collection is completed by different people at independent3 sites.* Mitigation: Data inconsistency is pursued by providing site access to standardized electronic case-report forms.Lack of Control GroupInterpretation of data may be limited since real-world studies do not utilize placebo-controlled armsConfounding VariablesConfounding variables are not controllable, which may impact the relationship between the exposure and outcome.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.* Protofibrils are thought to be the most toxic AB species that contribute to brain damage in AD and play a major role in the cognitive decline of this progressive and devastating disease. Protofibrils can cause neuronal and synaptic damage in the brain, which can subsequently adversely affect cognitive function through multiple mechanisms.1 The mechanism by which this occurs has been reported not only by increasing the formation of insoluble AB plaques, but also by directly damaging signaling between neurons and other cells. It is believed that reducing protofibrils may reduce neuronal damage and cognitive impairment, potentially preventing the progression of AD.2For more details, please visit: https://www.eisai.com/news/2025/pdf/enews202552pdf.pdfMEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@Eisai.comBiogen Inc.Madeleine Shin+1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Tim Power+ 1-781-464-2442IR@biogen.com  Copyright 2025 JCN Newswire via SeaPRwire.com.